Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference

Rhea-AI Summary

Pyxis Oncology (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers, has announced its participation in the Leerink Partners Global Healthcare Conference in Miami, Florida.

The company's President and CEO, Dr. Lara S. Sullivan, will engage in a fireside chat scheduled for March 10, 2025, at 2:20 PM EST. Investors and interested parties can access both the live webcast and replay of the presentation through the Events & Presentations page in the Investor Relations section of Pyxis Oncology's website at ir.pyxisoncology.com.

News Market Reaction – PYXS

-6.72%

-6.72% Session move

In the trading session that priced this news, PYXS declined 6.72%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday, March 10, 2025 at 2:20 PM EST at the Leerink Partners Global Healthcare Conference in Miami, Florida.

A live webcast and replay of the fireside chat will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.

About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. is a clinical stage company focused on defeating difficult-to-treat cancers. The company is efficiently building next generation therapeutics that hold the potential for monotherapy and combination indications. PYX-201, an antibody-drug conjugate (ADC) that uniquely targets EDB+FN, a non-cellular structural component of the tumor extracellular matrix, is being evaluated in ongoing Phase 1 clinical studies in multiple types of solid tumors. PYX-201 is designed to directly kill cancer cells and to address factors in the microenvironment that enable the uncontrolled proliferation and immune evasion of malignant tumors.

To learn more, visit www.pyxisoncology.com or follow us on X (formerly known as Twitter) and LinkedIn.

Pyxis Oncology Contact
Pamela Connealy
CFO and COO
ir@pyxisoncology.com

FAQ

When is Pyxis Oncology (PYXS) presenting at the Leerink Partners Healthcare Conference 2025?

Pyxis Oncology will present on March 10, 2025, at 2:20 PM EST in Miami, Florida.

How can investors watch Pyxis Oncology's (PYXS) Leerink Conference presentation?

Investors can watch the live webcast and replay through the Events & Presentations page on Pyxis Oncology's investor relations website at ir.pyxisoncology.com.

What type of company is Pyxis Oncology (PYXS)?

Pyxis Oncology is a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers.

Who will represent Pyxis Oncology (PYXS) at the 2025 Leerink Partners Conference?

Dr. Lara S. Sullivan, President and Chief Executive Officer of Pyxis Oncology, will represent the company in a fireside chat.